LEX Diagnostics
Krzysztof Gizynski is a Senior Reagent Development Scientist at LEX Diagnostics, specializing in the development of point-of-care devices for microbial diagnostics and optimization of RT-qPCR formulations. Previously, as a Clinical Assay Research Scientist at QuantuMDx Group Limited, Krzysztof focused on assays for detecting M. tuberculosis. In the role of Senior Scientist at SPOREGEN LIMITED, involvement included developing Luminex assays for Clostridium difficile and investigating Bacillus bacteriophages. Krzysztof also gained experience as a Postdoctoral Research Fellow at The University of Nottingham, working on genetic manipulations of Clostridium acetobutylicum and Geobacillus thermoglucosidasius. Early career experience included a placement at CEFAS, where Krzysztof contributed to virus detection quality control projects. Krzysztof holds a PhD in Molecular Microbiology from Newcastle University.
LEX Diagnostics
LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care. Having solved the PCR cost problem, LEX focuses tightly on nasal and oral samples, and on viral pathogens, to avoid the other high-cost elements of traditional molecular diagnostic products. LEX Diagnostics is a spin-out from TTP plc, atechnology development company in the life science and medical device sector. The origins of the LEX technology lie in an internal R&D project to reduce the time it takes to get a result from a PCR test. It formed a company when it became clear the solution also reduced the cost and size of any diagnostic device using it.LEX Diagnostics was founded in 2020 and is based in Melbourn, United Kingdom.